MBX Biosciences, Inc. (MBX) — Stock Price, Chart & Analysis
MBX Biosciences, Inc. (MBX) is a Healthcare stock currently trading at $67.82, up 1.06% on the day. It carries a market capitalization of $3.27B. Over the past 52 weeks, MBX has traded between $9.63 and $72.64. MBX Biosciences, Inc. does not currently pay a regular dividend. View the live MBX chart, technical opinion, analyst ratings, fundamentals and latest news below.
MBX Biosciences, Inc. (MBX) key data
| Price | $67.82 |
| Change (today) | +1.06% |
| Previous close | $67.11 |
| Market cap | $3.27B |
| EPS (TTM) | $-2.39 |
| 52-week high | $72.64 |
| 52-week low | $9.63 |
| Avg. volume | 837.0K |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently asked questions about MBX Biosciences, Inc. (MBX)
How much does one share of MBX Biosciences, Inc. cost?
As of the latest update, one share of MBX Biosciences, Inc. (MBX) trades at $67.82 (+1.06% today).
What is MBX Biosciences, Inc.'s market cap?
MBX Biosciences, Inc. has a market capitalization of approximately $3.27B.
What is MBX Biosciences, Inc.'s earnings per share (EPS)?
MBX Biosciences, Inc.'s trailing twelve-month EPS is $-2.39.
Does MBX Biosciences, Inc. pay a dividend?
MBX Biosciences, Inc. does not currently pay a regular dividend.
What is MBX Biosciences, Inc.'s 52-week trading range?
Over the past year, MBX has traded between $9.63 and $72.64.
What is the analyst price target for MBX Biosciences, Inc.?
The mean analyst price target for MBX Biosciences, Inc. is $84.80. This is informational only and not investment advice.
Latest MBX Biosciences, Inc. (MBX) news
- MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate HighlightsNews · Aug 6, 2026
- MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of GrowthNews · Jul 13, 2026
- MBX Biosciences Shares Fall Despite Positive One-Year Trial Results for Canvuparatide (MBX)News · Jun 12, 2026
- MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic HypoparathyroidismNews · Jun 12, 2026
- Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 RunNews · May 27, 2026
- MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate HighlightsNews · May 7, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live MBX dashboard…